Definium Therapeutics, Inc. (DFTX)
NasdaqGS · Biotechnology
Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.
Price history
Daily closes and volumeAI Analysis Generated from the indicator readings below. Educational only.
Definium Therapeutics, Inc. is trading at $35.67, down 0.92% on the session. The 50 day average sits at $38.87 and the 200 day at $28.82, which puts the stock in a uptrend. RSI is at 47.1, which reads as neutral, and MACD is bullish crossover. Volume is above average.
The nearest support is around $32.84 with resistance near $38.04, so that band frames the current range. Average daily movement is roughly $1.90, or about 5.3% of the share price, which is what any stop placement has to allow for. The overall health score of 50 out of 100 combines a trend score of 53, momentum of 56 and a risk score of 36.
Technical indicators
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Company website